Browse by author
Lookup NU author(s): Dr Penelope Taylor,
Dr Brian Angus,
Professor Graham Jackson,
Dr Helen Lucraft,
Professor Stephen Proctor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Two hundred untreated patients with low grade NHL (KIEL), including 155 follicular NHL, were randomized to six courses of treatment with chlorambucil 20 mg m-2 for 3 days and dexamethasone 4 mg bd for 5 days (CD) vs the same regimen plus oral idarubicin 10 mg m-2 for 3 days (CID). Responding patients could be randomized to no further treatment or maintenance treatment for up to 36 months with alpha interferon. Complete remissions/CRu were more frequent in the CID arm (35% vs 24%) but the overall response rate was similar; 87/91 (96%) vs 86/92 (93%). Overall survival (OS) did not differ between the two arms. Time to treatment failure (TTTF) was prolonged in the CID arm, p = 0.03; median time 28 vs 19 months. TTTF for the B-cell follicular group alone was for CID (77 patients) 33 months vs 18 months for CD (78 patients). Interferon conferred no apparent benefit. The Follicular Lymphoma International Prognostic Index (FLIPI) is confirmed as a good predictor of risk groups including a group of 23% with shorter survival. The addition of the oral anthracycline, idarubicin, led to a significant improvement in TTTF with low toxicity. The use of radiotherapy in this sub-group may have contributed to this result. CID is a potential for combination with antibody therapy particularly in older patient groups.
Author(s): Taylor, P. R. A., White, J. M., Prescott, R. J., Angus, B., Galloway, M. J., Jackson, G. H., Lessells, A. M., Lucraft, H. H., Summerfield, G. P., Proctor, S. J.
Publication type: Article
Publication status: Published
Journal: Leukemia and Lymphoma
Print publication date: 01/11/2006
ISSN (print): 1042-8194
ISSN (electronic): 1029-2403
PubMed id: 17107904
Altmetrics provided by Altmetric